

Aminocaproic acid injection, Epinephrine injection, Molindone tablets – Drug shortages

- The drug shortages of [aminocaproic acid](#) injection, [epinephrine](#) 0.1 mg/mL injection, and [molindone](#) tablets are ongoing. [Aminocaproic acid](#) injection, [epinephrine](#) injection, and [molindone](#) tablets have been unavailable for at least 90 days.
 - Hospira’s estimated availability of aminocaproic acid injection is late November 2017. Hospira estimates that the product will be fully recovered by March 2018.
 - Amphastar and Hospira’s estimated availability of epinephrine injection is November 2017. Epinephrine auto-injectors (eg, EpiPen®) are readily available.
 - Epic’s estimated availability of molindone tablets is unknown.

Product Description	NDC #
Aminocaproic acid 5 g/20 mL (250 mg/mL) injection	0409-4346-73, 0409-4346-09, 0409-4346-10
Epinephrine 0.1 mg/mL injection	76329-3316-1, 0409-4921-34
Molindone 5 mg, 10 mg and 25 mg tablets	64720-228-10, 64720-229-10, 64720-230-10

- Aminocaproic acid injection is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, fresh whole blood transfusions, fibrinogen infusions, and other emergency measures may be required.
- Epinephrine injection is indicated for intravenous injection in (1) treatment of acute hypersensitivity (anaphylactoid reactions to drugs, animal serums and other allergens), (2) treatment of acute asthmatic attacks to relieve bronchospasm not controlled by inhalation or subcutaneous administration of other solutions of the drug and (3) treatment and prophylaxis of cardiac arrest and attacks of transitory atrioventricular heart block with syncopal seizures (Stokes-Adams Syndrome).
- Molindone is indicated for the management of schizophrenia.